Chemicals momentum meets films margin pressure—expect moderation in Q2
SRF heads into Q2 results on the back of a record Q1, but guidance has signaled that Performance Films margins will normalize after temporary supply-driven gains. Expect strong chemicals growth to carry revenue; watch whether sequential margin contraction surprises or lands in line.
The setup: Growth meets margin headwinds
SRF delivered a record Q1 FY27—₹5,033 Cr revenue (+32% YoY), operational EBIT +61%, PAT ₹759 Cr (+76% YoY)—powered by strong chemicals momentum (refrigerant volumes) and temporary tailwinds in Performance Films from supply disruptions at competitors. Q2 will test whether that momentum holds when those tailwinds recede. Management has explicitly warned that Q2 should see margin normalization in Performance Films, a segment that contributed outsized profits in Q1.
~₹4,047 Cr
18.2% YoY growth, steady chemicals momentum
~₹471 Cr
Prabhudas Lilladher; 133% YoY but off a low base
~₹887 Cr
64.9% YoY growth; watch margin %
15–20% FY27
Q1 delivered 26%; Q2 sustainability key
Strong vs weak: What the print will reveal
A strong Q2 would show: (1) Chemicals segment sustaining mid-to-high 20% growth, (2) Performance Films EBITDA margin in the 35–38% range (down from Q1's elevated ~40%, but not collapsing), (3) overall EBITDA margin holding above 21–22%, and (4) no guidance cuts on FY27 capex or full-year chemical volumes. A weak print would signal: (1) Chemicals growth slipping below 15%, (2) Films margins cratering below 30%, (3) EBITDA margin compression beyond 200 bps sequentially, or (4) management reducing FY27 chemicals guidance or signaling extended margin pressure into H2.
On track?
Yes, for FY27 guidance. Q1 was a beat on both growth and profit; the trajectory supports the 15–20% chemicals growth and the ₹250 Cr BOPET thick-film capex announced in July. Chemicals has been the anchor—refrigerant demand and the shift toward higher-margin applications in refrigeration and electrical are intact. The risk is all in Performance Films: if the supply-disruption tailwinds fade faster than expected and pricing reverts, Q2–Q3 could be volatile. The new CHRO appointment (Oct 5) after a sudden resignation (Sep 23) is routine housekeeping and should not affect operations.
What the Street says
Since last quarter: Filing scan
Jul 22
₹250 Cr investment, 25,000 MTPA capacity, 24-month timeline. Strategic to reduce thin-film exposure and target high-margin electrical/electronics applications.
BOPET thick-film capex approved
Jul 22
Routine; cash returned to shareholders mid-year.
Interim dividend (50% / ₹5/share)
Jul 27
FY23 income-tax rectification order; significant one-time benefit, reduces future tax tail risk.
Tax demand reduced (₹327.44 Cr → ₹9.46 Cr)
Sep 23–Oct 5
Geeta Jadhav resigned (Sep 23, personal reasons); Jyothsana Vasudevan appointed (Oct 5). No operational impact; routine succession.
CHRO resignation then appointment
Oct 1
ITC disallowance claim for FY22; Vadodara-II commissioner. Contingent liability; outcome TBD.
GST show cause notice (₹266.32 Cr)
Sep 19–25
Promoter group internal restructuring; no change to effective promoter holding (50.26%). Routine.
Kama Holdings/Realty inter-se transfers
What to watch on result day
1 · Performance Films EBITDA margin
The headline risk. Q1 benefited from supply-side disruptions at competitors. Q2 is the test of how much margin normalizes and whether it's a 1–2 quarter reset or a structural shift. Watch for sequential margin contraction and manage expectations accordingly.
2 · Chemicals growth and pricing
Q1 showed 26% growth in chemicals; FY27 guidance is 15–20%. Q2 will reveal whether the refrigerant cycle is sustained and whether pricing holds. A deceleration below 15% signals caution; sustained mid-20s signals confidence.
3 · Capex and margin investment thesis
Management will likely detail progress on the ₹250 Cr BOPET thick-film line (25,000 MTPA, 24-month timeline). Any capex acceleration or delay, or commentary on expected margin improvement post-commissioning, will shape H2 FY27 and FY28 visibility.
SRF enters Q2 off a record Q1, but with a headwind: management has flagged that the temporary margin boost from competitor supply disruptions will normalize in Q2. Expect revenue growth to remain solid (18–20% YoY) from chemicals momentum, but watch for sequential profit margin compression. The Street is neutral with upside to ₹3,001 (20% higher), pending clarity on whether margin normalization is transient and whether chemicals growth is durable. Results will clarify the sustainability of the chemicals cycle and the trajectory of the BOPET capex—a structural margin-protection play that will matter for FY28 and beyond.
Informational and educational content only. Not investment advice.